MiniMed announced has picked up FDA clearance of its tubeless insulin pump, the MiniMed Fit.
The device is engineered to deliver diabetes patients up to seven days of wear and a 300-unit insulin capacity controlled through a smartphone application.
MiniMed Fit expands the company's insulin delivery portfolio and brings its automated insulin delivery tech to a tubeless design for the first time. The company says MiniMed Fit reduces the number of pump changes and simplifies daily diabetes management decisions.
The FDA clearance announcement comes just days after MiniMed competitor Tandem Diabetes Care announced FDA clearance for its tubeless insulin delivery device, Tandem Mobi.
While both systems rely on insulin cartridge technology, MiniMed Fit has a 300-unit insulin cartridge integrated into a disposable, wearable patch rather than a separate, refillable cartridge inserted into a reusable pump.
"Clearing FDA ahead of schedule is more proof we're executing our strategy,” said Que Dallara, CEO of MiniMed, in a statement.
“It puts MiniMed Fit in U.S. customers' hands sooner, and the pharmacy channel makes it easier to get."
The MiniMed Fit launch is expected to begin with a phased rollout in the U.S. in spring 2027, following an early customer experience phase expected to begin in MiniMed's fourth quarter of fiscal year 2027.
In preparation for launch, the company has been building manufacturing capacity and commercial infrastructure alongside the regulatory process. MiniMed plans to “significantly” expand its manufacturing capacity as commercialization progresses to support growing demand.
MiniMed Fit’s commercial launch represents one of numerous milestones reached for the independent company, which recently broke away from Medtronic’s diabetes business.
The company gained FDA clearance for its smallest insulin pump yet and closed its Nasdaq IPO in March, raising $560 million in gross proceeds. Medtronic retained about 90% ownership of the company following the offering.